Innoviva reported third-quarter 2026 results with total revenue of $106.1 million, down 1.6% from $107.8 million a year earlier, while U.S. net product sales rose 45% to $43.3 million. The company swung to a net loss of $73.9 million, or $1.03 per basic share, mainly because of unfavorable fair value changes in its equity and long-term investments, and it reaffirmed its 2026 guidance of at least $150 million in U.S. net product sales.
Total revenue was $106.1 million versus $107.8 million in Q3 2025; gross royalty revenue from GSK was stable at $58.1 million.
Net loss of $73.9 million, or $1.03 per basic share, compared with net income of $89.9 million in Q3 2025, driven by a $139.5 million net unfavorable fair value change in equity and long-term investments.
Income from operations rose 21.9% to $42.2 million, and cash and cash equivalents totaled $581.4 million as of September 30, 2026.
During Q3 2026 the company repurchased 1,226,948 shares for $26.3 million under its $125 million buyback program.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Innoviva, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$411.33M
+14.7%
$3.30
+816.7%
65.9%
FY2024
$358.71M
+15.5%
$0.36
-83.6%
6.5%
FY2023
$310.46M
-6.3%
$2.20
-7.2%
57.9%
FY2022
$331.34M
-15.4%
$2.37
-17.4%
64.6%
FY2021
$391.87M
+16.4%
$2.87
+42.1%
67.8%
Frequently asked questions
When is Innoviva's next earnings date?
Innoviva has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Innoviva earn last quarter?
For the quarter ended Sep 2026, Innoviva reported diluted EPS of $-1.03 (-195.4% year over year) on revenue of $106.12M (-1.6%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.